

### **Synonym**

Spike,S protein,Spike glycoprotein,S glycoprotein

#### Source

SARS-CoV-2 Spike Trimer Protein, His Tag (JN.1/Omicron) (SPN-C5221) is expressed from human 293 cells (HEK293). It contains AA Val 16 - Pro 1213 (Accession # OHD43416.1 (T19I,R21T,LPP24-

26Del,A27S,S50L,H69del,V70del,V127F,G142D,Y144del,F157S,R158G,N211d el,L212I,V213G,L216F,H245N,A264D,I332V,G339H,K356T,S371F,S373P,S375 F,T376A,R403K,D405N,R408S,K417N,N440K,V445H,G446S,N450D,L452W,L455S,N460K,S477N,T478K,N481K,V483del,E484K,F486P,Q498R,N501Y,Y5 05H,E554K,A570V,D614G,P621S,H655Y,N679K,P681R,N764K,D796Y,S939F,Q954H,N969K,P1143L,R683A,R685A,F817P,A892P,A899P,A942P,K986P,V987P)). The spike mutations are identified on the SARS-CoV-2 Omicron variant (Pango lineage: JN.1/Omicron). The recombinant protein is expressed from human 293 cells (HEK293) with T4 fibritin trimerization motif and a polyhistidine tag at the C-terminus. Proline substitutions (F817P, A892P, A899P, A942P, K986P, V987P) and alanine substitutions (R683A and R685A) are introduced to stabilize the trimeric prefusion state of SARS-CoV-2 S protein and abolish the furin cleavage site, respectively.

Predicted N-terminus: Val 16

#### **Molecular Characterization**

This protein carries a polyhistidine tag at the C-terminus.

The protein has a calculated MW of 137.5 kDa. The protein migrates as 150-180 kDa when calibrated against <u>Star Ribbon Pre-stained Protein Marker</u> under reducing (R) condition (SDS-PAGE) due to glycosylation.

# Endotoxin

Less than 1.0 EU per µg by the LAL method.

### **Purity**

>90% as determined by SDS-PAGE.

#### **Formulation**

Lyophilized from 0.22 µm filtered solution in PBS with trehalose as protectant.

Contact us for customized product form or formulation.

# Reconstitution

Please see Certificate of Analysis for specific instructions.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

### Storage


For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:


- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.

### **SDS-PAGE**



SARS-CoV-2 Spike Trimer Protein, His Tag (JN.1/Omicron) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90% (With <u>Star Ribbon Pre-stained Protein Marker</u>).

# **SEC-MALS**



The purity of SARS-CoV-2 Spike Trimer Protein, His Tag (JN.1/Omicron) (Cat. No. SPN-C5221) is more than 85% and the molecular weight of this protein is around 570-620 kDa verified by SEC-MALS.


Report






# **Bioactivity-ELISA**

SARS-CoV-2 Spike Trimer Protein, His Tag (JN.1/Omicron) ELISA 0.5 µg of Human ACE2, Fc Tag per well



Immobilized Human ACE2, Fc Tag (Cat. No. AC2-H5257) at 5  $\mu$ g/mL (100  $\mu$ L/well) can bind SARS-CoV-2 Spike Trimer Protein, His Tag (JN.1/Omicron) (Cat. No. SPN-C5221) with a linear range of 0.6-20 ng/mL (QC tested).

# SARS-CoV-2 Spike Trimer Protein, His Tag (JN.1/Omicron) ELISA 0.5 $\mu$ g of SARS-CoV-2 Spike Trimer Protein, His Tag (JN.1/Omicron) per well



Immobilized SARS-CoV-2 Spike Trimer Protein, His Tag (JN.1/Omicron) (Cat. No. SPN-C5221) at 5  $\mu$ g/mL (100  $\mu$ L/well) can bind Human ACE2, Fc Tag (Cat. No. AC2-H5257) with a linear range of 0.2-1 ng/mL (Routinely tested).

# Background

It's been reported that coronavirus can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion. The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity.

# **Clinical and Translational Updates**

